Patient description: The patient is a 53-year-old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is getting worse. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions of the head and face are detected. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. The serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). The patient's sister had the same problems. She was diagnosed with Paget's disease of bone when she was 52 years old. The diagnosis of Paget's Disease of Bone is confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Prostate Cancer Men >18 years of age. No upper age limit 2. Written informed consent approved by institutional review board should be explained to and signed by patient 3. Documentation of histologically confirmed adenocarcinoma of the prostate. Gleason score of any sum is allowed on this study. 4. Metastatic disease as evidenced by visceral involvement, bone disease, or PSA elevation. 5. Patients should meet the of androgen independent prostate cancer (AIPC). Patients would fulfill these if they continue to progress despite complete androgen blockade (surgical or medical castration with anti-androgen) and despite an anti-androgen withdrawal trial. Failing anti-androgen withdrawal is defined as no decline by 25% or more 3-weeks after stopping anti-androgens. Progression on hormonal therapy is defined as ANY of the following PSA: 2 consecutive rising PSA values, at least 14-days apart, each being > 5 ng/ml For patients with visceral measurable disease, progression is defined as an increase by 50% or more in the size of measurable areas, or any development of new lesions For patients with bone-only disease, progression is defined as the appearance of 2 or more new areas of abnormal uptake on a bone scan, when compared to prior imaging studies. Changes in the uptake of already existing lesions will NOT be used to define progressive disease For patients with bone AND visceral disease, fulfilling any of the in 5.2 or 5.3 is sufficient to define progression. 6. Castration levels of testosterone (< 50 ng/dl) achieved via medical or surgical castration. Patients should continue on LHRH agonists throughout if this is the method used to achieve castration. 7. Life expectancy of at least 6 months 8. Adequate hematologic, renal, and liver function as evidenced by the following WBC > 2000 ANC > 1000 Platelet count > 100,000 HgB > 9.0 g/dl, Creatinine < 2 Total bilirubin < 2x upper limit of normal  presence of brain metastases 2. Known HIV+ status 3. ECOG performance status of 2 or higher 4. Use of investigational agents within 4 weeks of starting 5. Patients with prior exposure to more than one chemotherapy program Patients who have received one chemotherapy schedule can be enrolled on study and receive GM-CSF (the maintenance arm) if their last chemotherapy was taxotere, given within the past 12 weeks, and they have demonstrated NO evidence of progression radiographically and biochemically. Prior exposure to steroids is NOT an  6. Patients with other active malignancies (excluding non-melanoma skin cancers)are excluded. Prior malignancies are not as long as last treatment for such malignancies was over 5 years prior to enrollment. 7. Treatment with investigational products are NOT an  if therapy was last received over 4 weeks prior to enrollment. 8. Any medical intervention or other condition which, in the opinion of the principle investigator, could compromise adherence with study requirements